285 related articles for article (PubMed ID: 17563752)
41. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
Dang DT; Chun SY; Burkitt K; Abe M; Chen S; Havre P; Mabjeesh NJ; Heath EI; Vogelzang NJ; Cruz-Correa M; Blayney DW; Ensminger WD; St Croix B; Dang NH; Dang LH
Cancer Res; 2008 Mar; 68(6):1872-80. PubMed ID: 18339868
[TBL] [Abstract][Full Text] [Related]
42. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells.
Jung SN; Yang WK; Kim J; Kim HS; Kim EJ; Yun H; Park H; Kim SS; Choe W; Kang I; Ha J
Carcinogenesis; 2008 Apr; 29(4):713-21. PubMed ID: 18258605
[TBL] [Abstract][Full Text] [Related]
43. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies.
Martinive P; Defresne F; Bouzin C; Saliez J; Lair F; Grégoire V; Michiels C; Dessy C; Feron O
Cancer Res; 2006 Dec; 66(24):11736-44. PubMed ID: 17178869
[TBL] [Abstract][Full Text] [Related]
44. The hypoxia-inducible factor and tumor progression along the angiogenic pathway.
Brahimi-Horn MC; Pouysségur J
Int Rev Cytol; 2005; 242():157-213. PubMed ID: 15598469
[TBL] [Abstract][Full Text] [Related]
45. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.
Hsieh CH; Wu CP; Lee HT; Liang JA; Yu CY; Lin YJ
Free Radic Biol Med; 2012 Aug; 53(4):649-58. PubMed ID: 22713363
[TBL] [Abstract][Full Text] [Related]
46. Targeting hypoxia cell signaling for cancer therapy.
Melillo G
Cancer Metastasis Rev; 2007 Jun; 26(2):341-52. PubMed ID: 17415529
[TBL] [Abstract][Full Text] [Related]
47. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1.
Baugh JA; Gantier M; Li L; Byrne A; Buckley A; Donnelly SC
Biochem Biophys Res Commun; 2006 Sep; 347(4):895-903. PubMed ID: 16854377
[TBL] [Abstract][Full Text] [Related]
48. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.
Moeller BJ; Dreher MR; Rabbani ZN; Schroeder T; Cao Y; Li CY; Dewhirst MW
Cancer Cell; 2005 Aug; 8(2):99-110. PubMed ID: 16098463
[TBL] [Abstract][Full Text] [Related]
49. Inhibitory activity of the hypoxia-inducible factor-1 pathway by tartrolone C.
Yamazaki Y; Someno T; Minamiguchi K; Kawada M; Momose I; Kinoshita N; Doi H; Ikeda D
J Antibiot (Tokyo); 2006 Nov; 59(11):693-7. PubMed ID: 17256467
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.
Kostourou V; Troy H; Murray JF; Cullis ER; Whitley GS; Griffiths JR; Robinson SP
Neoplasia; 2004; 6(4):401-11. PubMed ID: 15256062
[TBL] [Abstract][Full Text] [Related]
51. Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.
Leung E; Cairns RA; Chaudary N; Vellanki RN; Kalliomaki T; Moriyama EH; Mujcic H; Wilson BC; Wouters BG; Hill R; Milosevic M
BMC Cancer; 2017 Jun; 17(1):418. PubMed ID: 28619042
[TBL] [Abstract][Full Text] [Related]
52. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12.
Gee MS; Koch CJ; Evans SM; Jenkins WT; Pletcher CH; Moore JS; Koblish HK; Lee J; Lord EM; Trinchieri G; Lee WM
Cancer Res; 1999 Oct; 59(19):4882-9. PubMed ID: 10519400
[TBL] [Abstract][Full Text] [Related]
53. Targeting the molecular basis for tumour hypoxia.
Carroll VA; Ashcroft M
Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
[TBL] [Abstract][Full Text] [Related]
54. Selective enhancement of hypoxic cell killing by tempol-regulated suicide gene expression.
Kagiya G; Ogawa R; Choudhuri R; Cook JA; Hatashita M; Tanaka Y; Koda K; Yamashita K; Kubo M; Kawakami F; Mitchell JB
Oncol Rep; 2015 Aug; 34(2):1065-73. PubMed ID: 26034980
[TBL] [Abstract][Full Text] [Related]
55. Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment.
Krishnamoorthy S; Honn KV
Cancer Metastasis Rev; 2011 Dec; 30(3-4):613-8. PubMed ID: 22042480
[TBL] [Abstract][Full Text] [Related]
56. Hypoxia and ionizing radiation: changes in adhesive properties and cell adhesion molecule expression in MG-63 three-dimensional tumor spheroids.
Indovina P; Ferrante A; Rainaldi G; Santini MT
Cell Commun Adhes; 2006; 13(3):185-98. PubMed ID: 16798617
[TBL] [Abstract][Full Text] [Related]
57. Using YC-1 to overcome the radioresistance of hypoxic cancer cells.
Moon SY; Chang HW; Roh JL; Kim GC; Choi SH; Lee SW; Cho KJ; Nam SY; Kim SY
Oral Oncol; 2009 Oct; 45(10):915-9. PubMed ID: 19457706
[TBL] [Abstract][Full Text] [Related]
58. Induction of complete regressions of oncogene-induced breast tumors in mice.
Benezra R; Henke E; Ciarrocchi A; Ruzinova M; Solit D; Rosen N; Nolan D; Mittal V; de Candia P
Cold Spring Harb Symp Quant Biol; 2005; 70():375-81. PubMed ID: 16869774
[TBL] [Abstract][Full Text] [Related]
59. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
Meijer TW; Kaanders JH; Span PN; Bussink J
Clin Cancer Res; 2012 Oct; 18(20):5585-94. PubMed ID: 23071360
[TBL] [Abstract][Full Text] [Related]
60. The proliferative response of hela cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: an analogue for studying some properties of in vivo solid cancers.
Anderson KM; Tsui P; Guinan P; Rubenstein M
Anticancer Res; 2006; 26(6B):4155-62. PubMed ID: 17201127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
